



2023 half-year results: publication postponed to end of September

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

Press release on August 22, 2023 after market close

Following the cyberattack that targeted us on June 19, exceptional measures were immediately taken to contain it and a crisis unit including experts dedicated to cybersecurity was set up to assess the impact on our systems and quickly organize the remediation operations necessary for the continuity of our activities. This attack led to a temporary slowdown or interruption of some of our services: consequences which were nonetheless contained thanks to the responsiveness and mobilization of our teams.

The remediation continued over the summer and to date, we have restarted the critical and important applications while having further strengthened our IT infrastructures. This allows us to operate our priority processes normally again at all of our sites around the world.

These operations have made it possible to gradually restore fully functional financial systems and we will be able to publish our half-year results on September 28 (the presentation of the accounts and the detailed half-year financial report will, for their part, be published on October 6).

Always working for animal health

At Virbac, we provide innovative solutions to veterinarians, breeders and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services makes it possible to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and together shaping the future of animal health.



5,400
EMPLOYEES
+5.2% compared to 2021



SALES
SUBSIDIARIES
IN 33 COUNTRIES

60%
COMPANION
ANIMALS



40%
FARM
ANIMALS

SALES
2022
6th WORLDWIDE

Ranking of veterinary drug manufacturers
+9.6% at constant exchange rates and scope compared to 2021



PRODUCTION
SITES
IN 10 COUNTRIES



R&D
CENTERS ON
5 CONTINENTS